- The Wall Street Journal•yesterday
Pfizer’s $14 billion deal to buy Medivation and its prostate-cancer drug Xtandi is the latest in a long line of big pharmaceutical company acquisitions of smaller companies with prized assets. Here is ...
- ETF Trends•2 days ago
Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals ...
Merck & Co., Inc. (MRK)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||62.75 x 100|
|Ask||66.87 x 1000|
|Day's Range||63.37 - 63.88|
|52wk Range||47.97 - 64.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||34.88|
|Avg Vol (3m)||9,889,915|
|Dividend & Yield||1.84 (2.90%)|